Company Filing History:
3 out of 60 
1 out of 3,539 
1 out of 3 Years Active: 2022-2025
Title: Kendal T Ryter: Innovator in Vaccine Adjuvants and TLR Ligands
Introduction
Kendal T Ryter is a notable inventor based in Hamilton, Montana, who has made significant contributions to the field of biomedical research. With a total of five patents to his name, Ryter's work focuses on innovative compounds that have the potential to enhance vaccine efficacy and address various health conditions.
Latest Patents
Among his latest patents, Ryter has developed diaryl trehalose compounds, which are disclosed for their use as vaccine adjuvants. These compounds are designed to improve the immune response to vaccines. Additionally, he has patented toll-like receptor (TLR) ligands that feature an allose-based core. These ligands are stable in aqueous formulations and are useful in treating, preventing, or reducing susceptibility to diseases mediated by TLRs, including cancer, infectious diseases, allergies, autoimmune diseases, sepsis, and ischemia reperfusion.
Career Highlights
Kendal T Ryter has had a distinguished career, working with esteemed institutions such as the University of Montana and the National Institutes of Health, a component of the US Department of Health & Human Services. His research has contributed to advancements in medical science and public health.
Collaborations
Ryter has collaborated with notable colleagues, including George Ettenger and David Burkhart, to further his research and development efforts in the biomedical field.
Conclusion
Kendal T Ryter's innovative work in developing diaryl trehalose compounds and TLR ligands showcases his commitment to advancing medical science. His contributions have the potential to significantly impact vaccine development and treatment strategies for various diseases.